<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03440814</url>
  </required_header>
  <id_info>
    <org_study_id>C601</org_study_id>
    <nct_id>NCT03440814</nct_id>
  </id_info>
  <brief_title>A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soleno Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soleno Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this is study is to evaluate the effects of DCCR (diazoxide choline controlled
      release tablets) in children and adults with Prader-Willi syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperphagia Score</measure>
    <time_frame>Baseline to Week 13</time_frame>
    <description>Change in hyperphagia-related behavior as measured by total score of a Hyperphagia Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body fat mass (DXA)</measure>
    <time_frame>Baseline to Week 13</time_frame>
    <description>Change in Body Fat Mass from Baseline to Week 13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I</measure>
    <time_frame>at Week 13</time_frame>
    <description>Clinical Global Impression of Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver GI-C</measure>
    <time_frame>at Week 13</time_frame>
    <description>Caregiver Global Impression of Change</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>DCCR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 - 450 mg DCCR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>75 - 450 mg placebo for DCCR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCCR</intervention_name>
    <description>Once daily oral administration</description>
    <arm_group_label>DCCR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for DCCR</intervention_name>
    <description>Once daily oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide voluntary, written informed consent (parent(s) / legal guardian(s) of
             patient); provide voluntary, written assent (patients, as appropriate)

          -  Genetically-confirmed Prader-Willi syndrome

          -  In a stable care setting for at least 6 months prior to Visit 1

          -  Caregiver must have been caring for the patient for at least 6 months prior to Visit 1

        Exclusion Criteria:

          -  Have participated in an interventional clinical study (i.e., investigational drug or
             device, approved drugs or device evaluated for unapproved use) within prior 3 months

          -  Positive urine pregnancy test (in females of child-bearing potential) or females who
             are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during
             or within 30 days after study participation

          -  Any other known disease and/or condition, which would prevent, in the opinion of the
             Investigator, the patient from completing all study visits and assessments required by
             the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>C601 Project Manager</last_name>
    <phone>650-353-2051</phone>
    <email>C601ProjectManager@soleno.life</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Kearns, BSN</last_name>
      <phone>206-987-2640</phone>
      <email>sue.kearns@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Parisa Salehi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PWS</keyword>
  <keyword>Prader-Willi Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Hyperphagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
    <mesh_term>Diazoxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

